A further ongoing ICI-adjuvant RCC trial is the Checkmate-914 phase III study, which analyzes nivolumab, an anti-PD-1 monoclonal antibody, alone or combined with ipilimumab, an anti-CTLA4 monoclonal antibody, vs placebo for 24 weeks in high-risk mostly ccRCC with pT2a (grade 3 or 4), pT2b/pT3/pT4 (any grade), N0, or any T (any grade) N1 after complete or partial nephrectomy [38]. Here, CTLA4 is linked to renal cell carcinoma.